Axsome Therapeutics (AXSM) Change in Receivables (2022 - 2026)

Axsome Therapeutics (AXSM) has 5 years of Change in Receivables data on file, last reported at $26.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables rose 37.13% year-over-year to $26.6 million; the trailing twelve-month figure through Mar 2026 stood at $89.7 million (up 49.54% YoY), and the FY2025 full-year result was $82.5 million, up 74.78% from the prior year.
• Change in Receivables fell to $26.6 million in Q1 2026, from $28.0 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $37.4 million in Q2 2025 to a low of -$2.3 million in Q3 2025.
• A 5-year average of $15.7 million and a median of $17.4 million in 2022 frame the typical range for Change in Receivables.
• Peak annual rise in Change in Receivables reached 193.21% in 2025, while the deepest fall reached 161.75% in 2025.
• Tracing AXSM's Change in Receivables over 5 years: stood at $17.4 million in 2022, then slipped by 5.7% to $16.4 million in 2023, then rose by 9.14% to $17.9 million in 2024, then soared by 56.14% to $28.0 million in 2025, then slipped by 4.86% to $26.6 million in 2026.
• Business Quant data shows AXSM's Change in Receivables at $26.6 million in Q1 2026, $28.0 million in Q4 2025, and -$2.3 million in Q3 2025.